Abstract: Aspects of the present disclosure include methods, apparatuses, and computer readable media for receiving at least one TP packet, computing a current data rate or an end time of a low throughput phase, determining if TP is in the low throughput phase, aggregating the at least one received TP packet or an ACK relating to the at least one received TP packet in response to determining that the TP is not in the low throughput phase, and transmitting the ACK to a sending device.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use these compounds, for example in a method of treatment of cardiac conditions.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: There is described a process for production of metal-coated virus particles or metallic nanoparticles, said process comprising admixing virus particles with plant material with reducing power and a metal salt, wherein the process can be provided in planta or ex planta and the virus particles aid the production of the metal-coated virus particles or metallic nanoparticles.

Abstract: There is described a process for production of metal-coated virus particles or metallic nanoparticles, said process comprising admixing virus particles with plant material with reducing power and a metal salt, wherein the process can be provided in planta or ex planta and the virus particles aid the production of the metal-coated virus particles or metallic nanoparticles.

Abstract: A method of producing a chimeric protein from ie a plant virus coding for such a protein. The method allows the production of large (ie 25 kDa) proteins which assemble with the virus in infected host cells and are arranged on the outer surface of chimeric viruses. A vector for the production of biologically useful proteins in such a manner is also disclosed.

Abstract: A bracket (90) fixedly supports a structural member (120) with respect to an aperture (128). The bracket (90) has a semicircular cross section body (100) with one end portion (94) for placement on the structural member. A second end portion (96) extends into aperture (128). The bracket body (100) has a plurality of longitudinally extending corrugations (92) along the body. A wedge shaped driving member (98) extends outward from the body (100) and extends between the first and second body portions (94) and (96). A clamp (130) and/or screws (188) fasten the first bracket body portion (94) to the structural member (120) or (180). In use, the bracket (90) is driven into the aperture (128) by striking the driving member (98). The driving member (98) and the corrugations (92) coact with the aperture (128) to provide a camming action, which expands the bracket body end (96) in at least one dimension to hold the bracket (90) tightly in the aperture (128).